Group 4 Created with Sketch.

‎ReachMD CME

Play All
92 Subscribers
Share Path Report
rss rss .
Continue Reading >>
<< Show Less
Featured Audio
Clinical Case Challenge: Navigating the HER2 Treatment Paradigm for Breast Cancer CME credits: 0.50
Valid until: 31-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/clinical-case-challenge-navigating-the-her2-treatment-paradigm-for-breast-cancer/13919/


This Clinical Case Challenge is designed to help improve clinical decision making for providers caring for patients with HER2+ breast cancer.
Newest Audio
Clinical Case Challenge: Navigating the HER2 Treatment Paradigm for Breast Cancer CME credits: 0.50
Valid until: 31-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/clinical-case-challenge-navigating-the-her2-treatment-paradigm-for-breast-cancer/13919/


This Clinical Case Challenge is designed to help improve clinical decision making for providers caring for patients with HER2+ breast cancer.
Navigating the HER2 Treatment Paradigm for Breast Cancer CME credits: 0.50
Valid until: 31-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-her2-treatment-paradigm-for-breast-cancer/13918/


This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment strategies for patients with HER2+ breast cancer.
Underserved PAH Populations: Why Don’t We Connect? CME credits: 1.00
Valid until: 29-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/underserved-pah-populations-why-dont-we-connect/13718/


Many pulmonary arterial hypertension (PAH) patients remain undiscovered, undiagnosed, and underserved. The reasons for this are many-fold, but central to the treatment of these patients is a need to make PAH care more accessible, affordable, and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. That’s why this program explores myriad aspects of finding means to discover, connect with, and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive, and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients, and making the most of the developing practices of telemedicine.
A New Option for Cardiorenal Protection for Patients with CKD in T2D CME credits: 0.25
Valid until: 29-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/a-new-option-for-cardiorenal-protection-for-patients-with-ckd-in-t2d/13809/


Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.
Strategies for Optimizing Timeliness of Diagnosis & Treatment of Patients with Lung Cancer During Global Crises CME credits: 1.25
Valid until: 19-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-optimizing-timeliness-of-diagnosis-treatment-of-patients-with-lung-cancer-during-global-crises/13389/


A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.
Personalizing NSCLC: The Optimal Applicability of NGS and Liquid Biopsy CME credits: 0.25
Valid until: 15-07-2023
Claim your CME credit at https://reachmd.com/programs/cme/personalizing-nsclc-the-optimal-applicability-of-ngs-and-liquid-biopsy/13834/


There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022 CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-updates-from-asco-2022/13825/


A plethora of new data for multiple myeloma were presented at ASCO 2022. Hear Dr. Shaji Kuman and Dr. Maria-Victoria Mateos discuss the most relevant findings and which emerging strategies look promising for patients.
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-optimizing-treatment-selection-in-relapsed-or-refractory-multiple-myeloma/13823/


Patients with multiple myeloma inevitably experience disease relapse, which is challenging. Rapid therapeutic advances have heralded an increasing number of efficacious targeted strategies and combination therapies for patients after a first relapse or in those with heavily pretreated disease. However, selecting the optimal regimen requires a individualized approach. Hear how Dr. Amrita Krishnan and Dr. Morie Gertz translate the evolving clinical data into their clinical practices and what factors influence their choices to improve durable responses and outcomes for patients with relapsed/refractory multiple myeloma.
Keeping Pace in Hematologic Malignancies: Newly Diagnosed Multiple Myeloma CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-newly-diagnosed-multiple-myeloma/13822/


Significant progress has been made with induction and initial treatment of multiple myeloma, leading to longer and deeper remissions for patients. Yet, how do you decide which regimen is best? Hear how Dr. Monique Hartley-Brown and Dr. Shonali Midha navigate the treatment of their newly diagnosed patients and what factors they consider when selecting a regimen.
Load More Audio